Although glycoprotein Ia/IIa (GPIa/IIa, integrin ␣ 2 ␤ 1 ) has established its role as a collagen receptor, it remains unclear whether GPIa/IIa mediates activation signals. In this study, we show that rhodocytin, purified from the Calloselasma rhodostoma venom, induces platelet aggregation, which can be blocked by anti-GPIa monoclonal antibodies. Studies with rhodocytin-coupled beads and liposomes loaded with recombinant GPIa/IIa demonstrated that rhodocytin directly binds to GPIa/IIa independently of divalent cations. In vitro kinase assays and Western blotting of GPIa immunoprecipitates revealed that Src and Lyn constitutively associate with GPIa/IIa and that Src activity increases transiently after rhodocytin stimulation. Src specifically associates with p130 Crk-associated substrate (Cas) in a manner dependent upon Cas phosphorylation, suggesting that Src is responsible for Cas tyrosine phosphorylation. While all these phenomena occur early after rhodocytin stimulation in a cAMP-resistant manner, tyrosine phosphorylation of Syk and phospholipase C␥2, intracellular Ca 2؉ mobilization, and platelet aggregation occur later in a cAMP-sensitive manner. Cytochalasin D, which interferes with actin polymerization and blocks receptor clustering, inhibits all the rhodocytin-mediated signals we examined in this study. We suggest that rhodocytin, by clustering GPIa/IIa, activates GPIa/IIa-associated Src, which then mediates downstream activation signals.
Platelets adhere to collagen fibers exposed at sites of damage to the endothelial lining and become activated through specific membrane receptors for collagen. Many candidates have been proposed for putative collagen receptors on platelet membranes. Of these, GP Ia/IIa 1 and GPVI have now established their roles as collagen receptors (1) . It has been reported that human blood platelets that showed no response to collagen lacked the surface expression of GPIa/IIa or GPVI, indicating that GPIa/IIa and GPVI are collagen receptors (2) (3) (4) (5) (6) (7) (8) . Collagenrelated peptide (CRP) containing repeats of the Gly-Pro-Hyp sequence (9 -11) , and convulxin, which is a C-type lectin obtained from a tropical rattlesnake venom, are reported to be platelet agonists acting on GPVI (12, 13) . These proteins have been very useful for investigating the signal transduction pathways mediated by GPVI. Cross-linking of GPVI results in phosphorylation of the Fc receptor ␥ (FcR␥)-chain by the Src family kinases, Fyn and Lyn, then the binding of Syk to the ␥-chain, with resultant Syk activation (14 -17) . Syk activation appears to lie upstream of the tyrosine phosphorylation of PLC␥2, which releases intracellular calcium (18) .
On the other hand, relatively little has been elucidated regarding the GPIa/IIa-mediated signal transduction system. Although the role of GPIa/IIa as a collagen receptor is well established, whether GPIa/IIa also mediates activation signals has remained to be elucidated. Only recently, Kehrel et al. (10) has demonstrated that GPVI-deficient platelets showed increased fibrinogen binding in response to collagen but not to CRP. Since collagen but not CRP contains the binding sites for GPIa/IIa, it is suggested that GPIa/IIa also mediates certain activation signals leading to GPIIb/IIIa activation (10) . Studies with inhibitors have also suggested that GPIa/IIa can transduce activation signals in platelets; tyrosine phosphorylation of Syk or PLC␥2 induced by collagen was attenuated by pretreatment of anti-GPIa/IIa inhibitory antibodies or integrin ␤ 1 (GPIIa)-cleaving metalloproteinase, Jararhagin (19 -21) .
In contrast to GPVI-mediated platelet activation, there have been few GPIa/IIa agonists appropriate for investigating the GPIa/IIa-related signal transduction pathway. Aggretin, purified from snake venom, is reported to induce platelet aggregation acting as a GPIa/IIa agonist, but its functional property has not been fully elucidated (22) . JBS2, an anti-␣ 2 integrin monoclonal antibody (mAb) that promotes collagen binding to T-cells, stimulated tyrosine phosphorylation of PLC␥2 in human platelets. However, when Fc␥ receptor II (Fc␥RII) was blocked by an anti-Fc␥RII mAb, IV.3, JBS2 did not induce PLC␥2 phosphorylation, suggesting that platelet activation induced by this anti-␣2 mAb occurs mainly through Fc␥RII (20) . Thus, although it has been well established that GPIa/IIa plays a major role in platelet adhesion to collagen (1, 23, 24) , it remains unclear what signals GPIa/IIa mediates that finally lead to platelet activation.
Recently, we have isolated and characterized a functionally novel platelet agonist, designated as rhodocytin, from the Calloselasma rhodostoma venom (25) . We have suggested that rhodocytin belongs to the heterodimeric C-type lectin-like proteins and appears to induce platelet aggregation by interacting with GPIa/IIa (25, 26) . We found that the GPIa/IIa-mediated signal induces Syk and PLC␥2 activation, similar to GPVImediated signals. However, distinct from GPVI-mediated signals, tyrosine phosphorylation of Syk and PLC␥2 induced by GPIa/IIa stimulation is potently inhibited by acetylsalicylic acid (ASA) or cytochalasin D treatment. These findings suggest that Syk and PLC␥2 activation requires actin polymerization and that tyrosine phosphorylation of Syk and PLC␥2 is facilitated by the thromboxane A 2 (TXA 2 )-producing system in the GPIa/IIa-mediated signal transduction pathway. Susceptibility to ASA or cytochalasin D is reminiscent of collagen-induced platelet activation.
In this study, we present several lines of evidence to suggest that rhodocytin directly and specifically binds to GPIa/IIa and that this association is independent of divalent cations distinct from other integrin-ligand bindings. Our findings suggest that, upon rhodocytin stimulation, Src that constitutively associate with GPIa/IIa become activated, and several signaling molecules including Cas, Syk, and PLC␥2 undergo tyrosine phosphorylation. It is suggested that clustering of GPIa/IIa is necessary for the GPIa/IIa-mediated signal transduction, since all of these phenomena related to tyrosine phosphorylation are sensitive to cytochalasin D, which blocks actin polymerization.
EXPERIMENTAL PROCEDURES
Materials-Rhodocytin was purified from the venom of C. rhodostoma as described previously (25) . Anti-GPIa mAbs, 7E10B and 3C8A, were generated by one of us. Briefly, human platelets were used for immunizing 5-week-old Balb/c mice. The hybridomas obtained were screened by the reactivity to human GPIa-transfected Chinese hamster ovarian cells and human osteosarcoma-derived cell line, MG63, which expresses GPIa. Immunoprecipitation study using MG63 confirmed that clones 7E10B and 3C8A react with GPIa. Clone 7E10B is an inhibitory antibody, and clone 3C8A is a nonfunctional antibody, as determined by adhesion assays of platelets to collagen. Liposomes carrying recombinant fragments of GPIa/IIa (rGPIa/IIa liposome) were made by the methods of Staatz et al. (5) . Sepharose beads conjugated with 7E10B were used to purify the GPIa/IIa incorporated liposome. We have confirmed that rGPIa/IIa liposome has more than 90% purity by SDS-PAGE. Anti-GPIa mAb (6F1), anti-CD9 mAb, anti-GPIb mAb (WGA3), and collagen-related peptide (CRP) were kindly donated by Dr. B. S. Coller (Mt. Sinai Medical Center, New York), Dr. S. Nomura (Kansai Medical University, Osaka, Japan), Dr. M. Handa (Keio University, Tolyo, Japan) and Drs. M. Moroi and Y. Miura (Institute of Life Science, Kurume University, Fukuoka, Japan), respectively. The FcR␥-chain-deficient C57BL/6 (B6) mice and control B6 mice were generously provided by Dr. T. Takai (Tohoku University, Sendai, Japan).
The following materials were obtained from the indicated suppliers: anti-GPIa mAb (Gi9), Immnotech, Marseille, France; anti-Syk mAb and leupeptin, Wako Pure Chemical Industries, Ltd., Tokyo, Japan; anti-PLC␥2 polyclonal antibody (pAb), Santa Cruz, CA; the hybridoma of Fc␥RII mAb (clone IV.3), American Type Culture Collection, Manassas, VA; anti-phosphotyrosine (PY20) mAb, anti-Cas mAb, and anti-GPIIa mAb (clone 18), Transduction Laboratories, Lexington, KY; anti-GPIa mAb (A2-IIE10), anti-Src mAb (327), and anti-Lyn pAb, Upstate Biotechnology, Lake Placid, NY; type I collagen, Nycomed Pharma GMBH, Munich, Germany; the peptide Gly-Arg-Gly-Asp-Ser (GRGDS), Peptide Institute, Osaka, Japan; bovine serum albumin (BSA), prostaglandin I 2 (PGI 2 ), phenylmethylsulfonyl fluoride, sodium orthovanadate, Triton X-100, tetramethylrhodamine isothiocyanate-conjugated phalloidin, and enolase, Sigma; protein A-Sepharose and CNBr-activated Sepharose 4B beads, Amersham Pharmacia Biotech; peroxidase-conjugated goat anti-mouse IgG, Cappel Organ Teknika Co.; PGE 1 , Funakoshi, Tokyo, Japan; Fura2-AM, Dojindo Laboratories, Kumamoto, Japan; PP1, Biomol Research Laboratories, Inc., Plymouth Meeting, PA; PP2, Calbiochem; [␥- 32 P]ATP, PerkinElmer Life Sciences. Platelet Preparation-Venous blood from healthy drug-free volunteers was collected into a tube containing acid/citrate/dextrose (ACD).
Platelet-rich plasma (PRP) was obtained after centrifugation of whole blood at 160 ϫ g for 10 min. When indicated, PRP was incubated with 1 mM ASA for 30 min to exclude the secondary effects of TXA. The platelets were washed twice with 15% ACD and 100 nM PGI 2 and resuspended in HEPES buffer containing 138 mM NaCl, 3.3 mM NaHPO 4 , 2.9 mM KCl, 1.0 mM MgCl, 1 mg/ml glucose, and 20 mM HEPES, pH 7.4, at a concentration of 10 9 cells/ml. Thirty minutes before experiments, the platelet suspension was supplemented with 1 mM CaCl.
FcR ␥-Chain-deficient Mice and Preparation of Murine PlateletsFrom FcR␥-chain-deficient C57BL/6 (B6) mice and control B6 mice, blood (500 -900 l) was taken into a 1-ml plastic syringe containing 0.1 ml of ACD by cardiac puncture immediately after the mice died from deep ethyl ether anesthesia. PRP was obtained after centrifugation of whole blood at 160 ϫ g for 10 min. Residual blood after PRP had been removed was further diluted by adding 200 l of Tyrodes-HEPES buffer (134 mM NaCl, 2.9 mM KCl, 0.34 mM Na 2 HPO 4 , 12 mM NaHCO 3 , 20 mM HEPES, 1 mM MgCl 2 , pH 6.6). The mixture was centrifuged again, and the supernatant was obtained for the maximum recovery of platelets. After repeating this step several times, PRP was centrifuged at 1,000 ϫ g for 5 min in the presence of 100 nM PGI 2 and 15% ACD. The platelets were resuspended in Tyrodes-HEPES buffer, pH 7.3, at a concentration of 1.3 ϫ 10 8 cells/ml. Platelet Aggregation-Washed human platelets at a concentration of 2.0 ϫ 10 8 /ml or murine platelets at a concentration of 1.3 ϫ 10 8 cells/ml were activated by the indicated concentrations of agonists under continuous stirring at 1,000 rpm in a PA-100 platelet aggregation analyzer (Kowa, Tokyo, Japan). When indicated, platelets were pretreated with the indicated concentration of anti-GPIa mAbs, 1 M PGE 1 , 5 M PP1 or 5 M PP2 at 37°C for 5 min. The instrument was calibrated with a platelet suspension for zero light transmission and with buffer for 100% transmission.
Platelet Proteins That Bind to Rhodocytin-Thirty five g of purified rhodocytin was covalently coupled to 50 mg of CNBr-activated Sepharose 4B beads according to the manufacturer's instructions. One ml of platelet lysates (3.5 ϫ 10 9 cells) lysed by an equal volume of 2ϫ ice-cold lysis buffer(2% Triton X-100, 100 mM Tris/HCl, pH 7.5, 5 mM EGTA, 2 mM vanadate, 1 mM phenylmethylsulfonyl fluoride, and 100 g/ml of leupeptin) was clarified by centrifugation at 16,000 ϫ g for 5 min. The supernatant was precleared by 100 l of Sepharose 4B (50% slurry) for 1 h and then was split into two portions. One-half was incubated with 80 l of rhodocytin-bound Sepharose 4B, and the other half was incubated as the control with 80 l of Sepharose 4B for overnight. The beads were washed 5 times in 1ϫ lysis buffer, and proteins were eluted from the beads with 40 l of SDS reducing buffer (19) and were boiled for 5 min.
Adhesion of rGPIa/IIa Liposomes or Platelets to Rhodocytin-or Collagen-coated Plates-For the preparation of microtiter plates coated with rhodocytin or collagen, 100 l of the indicated concentrations of rhodocytin or collagen was added to each well of a 96-well flat-bottomed plate and was left to stand overnight at room temperature. After two cycles of washing with PBS, each well was blocked with 1% BSA in PBS for 30 min at room temperature. Before use, 1% BSA-containing PBS was heated at 80°C for 10 min and sterilized by filtration. One hundred l of rGPIa/IIa liposomes (2 g/ml) or washed platelet (1 ϫ 10 4 cells/ml) was then added to each well and incubated at 30°C for 3 h or 20 min, respectively. With rGPIa/IIa liposome, wells were incubated with biotinylated anti-GPIa mAb (3C8A) after removing unbound rGPIa/IIa liposome. rGPIa/IIa liposome binding was detected by horseradish peroxidase-conjugated avidin and visualized with o-phenylenediamine. The optical density was measured by a microplate reader (NOVAPATH, Bio-Rad). When platelet adhesion was measured, after removing unbound platelet, wells were incubated with 3% paraformaldehyde for 30 min at room temperature. After platelet membranes were lysed with 0.2% Triton X-100, they were stained by 0.1 g/ml tetramethylrhodamine isothiocyanate-conjugated phalloidin. Cells were viewed under a BH microscope (Olympus, Tokyo, Japan) and photographed on Fujicolor super G400 (Fujifilm, Tokyo, Japan). The number of adhered platelet was calculated on the photographs.
Immunoprecipitation and Western Blotting-After platelets were activated with rhodocytin for the indicated time intervals, reactions were terminated with an equal volume of ice-cold lysis buffer. The lysate was sonicated and centrifuged at 16,000 ϫ g for 5 min. The supernatant was precleared with protein A-Sepharose beads for 30 min at 4°C and then mixed with the indicated antibodies. The mixture was rotated for 1-2 h at 4°C and, after the addition of protein A-Sepharose beads, was further rotated for 1 h. The Sepharose beads were washed three times with 1ϫ lysis buffer. SDS reducing buffer was then added to the beads, followed by boiling for 3 min. The proteins were separated by 8% SDS-PAGE and electrophoretically transferred onto Clear Blot Membrane-P. The membranes were blocked with 1% BSA in PBS. After extensive washing with PBS containing 0.1% Tween 80, the immunoblots were incubated for 2 h with the indicated antibody. Antibody binding was detected by using peroxidase-conjugated goat anti-mouse IgG or anti-rabbit IgG and visualized with ECL chemiluminescence reaction reagents (Amersham Pharmacia Biotech) and Konica x-ray film (JX 8 ϫ 10, Konica Co., Tokyo, Japan). Where indicated, levels of tyrosine phosphorylation were quantified using PDI1400oe Scanner and Quantity One 2.5a software for Macintosh.
Immunoprecipitation Kinase Assay-After preclearing, the sample was split into two portions. One-half was used for immunoblotting as described elsewhere, and the other half was processed further for an in vitro kinase assay. For in vitro kinase assay, the beads were washed once with HEPES buffer (10 mM HEPES/NaOH, 1 mM vanadate, pH 8.0) and then incubated with 25 l of kinase reaction buffer (300 mM HEPES/NaOH, 15 mM MnCl 2 , 150 mM MgCl 2 , pH 8.0) with 10 l of acid-treated enolase. The reaction was initiated by the addition of 2 M ATP (10 Ci of [␥-
32 P]ATP). After 10 min at 20°C, reactions were stopped by the addition of Laemmli buffer and then subjected to boiling for 3 min. The proteins were separated under reducing conditions by 8% SDS-polyacrylamide gel electrophoresis (PAGE) and electrophoretically transferred onto Clear Blot Membrane-P (Atto, Tokyo, Japan). The membrane was treated with 1 M KOH for 60 min, dried, and visualized with a BAS-2000 PhosphorImager analyzer (Fuji Film, Japan). Where indicated, levels of radioactivity were quantified using PDI1400oe Scanner and Quantity One 2.5a software for Macintosh.
RESULTS

Effects of Anti-GPIa mAbs and an Anti-Fc␥RII mAb on
Rhodocytin-induced Platelet Aggregation-We previously reported that echicetin, which is GPIb-blocking snake venom, does not inhibit rhodocytin-induced platelet aggregation, suggesting that rhodocytin induces platelet aggregation independently of GPIb (25) . We also showed that rhodocytin induces platelet aggregation with a long lag time and that rhodocytininduced platelet aggregation is susceptible to ASA and cytochalasin D treatment (26) . Since all of these properties are reminiscent of collagen-induced platelet aggregation, we investigated the effect of antibodies directed against GPIa/IIa, which is one of the most important collagen receptors in platelets, on rhodocytin-induced platelet aggregation. A2-IIE10, a mAb directed against GPIa, potently blocked collagen-induced platelet aggregation, whereas Gi9, another mAb directed against GPIa, only partially inhibited collagen-induced platelet aggregation even at a concentration of 100 g/ml (Fig. 1A) . Rhodocytin (10 nM)-induced platelet aggregation was inhibited by 50 g/ml of Gi9 and was completely inhibited by A2-IIE10 at 25 g/ml, the concentration that also inhibits collagen-induced platelet aggregation (Fig. 1A) . Relatively high concentrations of anti-GPIa mAbs required for inhibition of rhodocytin-induced platelet aggregation imply that rhodocytin binds to GPIa/IIa with high affinity. Performed as negative control experiments, none of these anti-GPIa antibodies inhibited platelet aggregation induced by CRP or thrombin (Fig. 1A) . We confirmed that a blocking antibody against integrin-associated protein (B6H12), one of the platelet membrane proteins, had no effect on platelet aggregation induced by rhodocytin, even at a concentration of 100 g/ml (26) .
In contrast, IV.3 (anti-Fc␥RII blocking mAb), at a concentration that could completely inhibit platelet aggregation induced by a Fc␥RII-activating mAb (NNKY1-19), had virtually no effect on rhodocytin-induced platelet aggregation (Fig. 1B) . These findings suggest that rhodocytin interacts with GPIa/IIa but not with GPIb or Fc␥RII.
We also examined the effects of an anti-GPIa antibody on the interaction between platelets and immobilized rhodocytin. Washed platelets incubated with A2-IIE10 or control mouse IgG were added to rhodocytin-coated wells. Platelet binding was detected by staining with rhodamine-conjugated phalloidin. This binding was reduced to 12.5% of the control in the presence of 25 g/ml A2-IIE10 (data not shown). The fact that anti-GPIa antibody almost completely inhibits the association between platelets and rhodocytin indicates that GPIa/IIa is the major receptor responsible for the rhodocytin-platelet interaction.
Platelet Aggregation in FcR␥-chain Knockout Mice Induced by Rhodocytin-We investigated whether rhodocytin-mediated platelet aggregation is mediated by GPVI, one of the major collagen receptors. FcR␥-chain, which associates with GPVI is necessary for GPVI-mediated signal transduction, and collagen-related peptide (CRP), which is a specific GPVI agonist, fails to induce aggregation of platelets obtained from GPVI-deficient patients or FcR␥-chain knockout mice (18) . As shown in Fig. 2 , 20 nM rhodocytin induced aggregation of platelets obtained from Fc␥ Ϫ/Ϫ mice, whereas CRP up to the concentration of 1 g/ml failed to do so. In contrast, both rhodocytin and CRP elicited platelet aggregation with Fc␥ ϩ/ϩ mice. These findings suggest that rhodocytin induces platelet aggregation independently of GPVI.
Precipitation of GPIa/IIa in Platelet Lysates with Rhodocytin-coupled Beads-Based on the effects of specific mAbs, we have already suggested that rhodocytin induces platelet aggre-
FIG. 1. Effects of monoclonal antibodies against GPIa and
Fc␥RII on platelet aggregation induced by rhodocytin or other agonists. A, platelets were preincubated for 5 min with a vehicle solution (a), 25 g/ml of A2-IIE10 (b), and 100 g/ml of Gi9 (c). Platelets were then stimulated with 10 nM rhodocytin, 10 g/ml of collagen, 0.5 g/ml of CRP, or 0.2 units/ml of thrombin. Platelet aggregation was monitored by changes in light transmission. B, platelets were preincubated for 5 min with a vehicle solution (a and c) and 3 g/ml Fc␥RII-blocking mAb (IV.3) (b and d). Platelets were then stimulated with 10 nM rhodocytin (a and b) and 100 g/ml Fc␥RII-activating mAb (NNKY1-19) (c and d).
gation by interacting with GPIa/IIa, independently of GPIb (25, 26) . To confirm this hypothesis, we sought to determine whether rhodocytin-coupled beads bound to GPIa/IIa. Sepharose 4B beads were covalently coupled with rhodocytin and added to platelet lysates. Immunoblot analysis showed that rhodocytin-coupled Sepharose 4B beads effectively precipitated GPIa, whereas there was no recovery of GPIa with Sepharose 4B control beads (Fig. 3A) . On the other hand, neither rhodocytin-coupled Sepharose 4B beads nor Sepharose 4B beads as a control precipitated GPIb (Fig. 3B) . We could not detect coprecipitation of GPIIa in rhodocytin-coupled Sepharose 4B beads, although an anti-GPIIa antibody detected the presence of GPIIa in whole cell lysates of platelets. These findings suggest that rhodocytin binds to GPIa but not to GPIIa or GPIb.
GPIa/IIa or Platelet Adhesion to Immobilized Rhodocytin and the Effects of EDTA-To investigate whether rhodocytin binds directly or indirectly to GPIa (for example, via an unidentified protein which associates with GPIa/IIa), we evaluated the binding of liposomes carrying recombinant fragments of GPIa/IIa (rGPIa/IIa liposomes) to immobilized rhodocytin. As shown in Fig. 4 , rGPIa/IIa liposomes adhered to immobilized rhodocytin or collagen. This binding was potently blocked by 10 g/ml anti-GPIa blocking mAbs, 7E10B and Gi9. It is well known that the binding of integrins to their ligands requires the presence of divalent cations. The adhesion of rGPIa/ IIa liposomes to collagen was completely inhibited by 10 mM EDTA. To our surprise, EDTA did not inhibit the binding of rGPIa/IIa liposomes to rhodocytin at all. These findings suggest that rhodocytin specifically and directly interacts with GPIa/IIa, independently of divalent cations.
Platelet Aggregation, Intracellular Calcium Mobilization, Tyrosine Phosphorylation of Syk, and PLC␥2 Mediated by GPIa/ IIa Are Completely Inhibited by PGE 1 -We previously reported that rhodocytin-induced GPIa/IIa stimulation elicits tyrosine phosphorylation of Syk, subsequent PLC␥2 activation, and intracellular calcium mobilization, which finally leads to platelet aggregation and that these activation signals are inhibited by ASA treatment (26) . We also confirmed that Syk and PLC␥2 were activated even when platelets were pretreated with GRGDS peptides and EGTA, suggesting that this activation is aggregation-independent and that this is not mediated through GPIIb/IIIa (data not shown). In this study, we extended our study to evaluate the effects of PGE 1 , which increases the intracellular cAMP concentration. As shown in Fig. 5 , platelet aggregation, intracellular calcium mobilization, and tyrosine phosphorylation of Syk and PLC␥2 were completely inhibited by 1 M PGE 1 . Since several parameters of collagen-induced platelet activation are resistant to the elevation of intracellular cAMP (27) (28) (29) , we then sought to determine rhodocytin-induced activation signals, which were resistant to PGE 1 .
Rhodocytin Stimulation Induces Tyrosine Phosphorylation of an Adapter Protein, Cas, Independent of PGE 1 TreatmentRecently, several groups reported that Cas (Crk-associated pro- tein), an adapter protein of 130 kDa, and FAK are involved in cell activation induced by cross-linking of ␤ 1 integrin or cell adhesion to extracellular matrix including collagen in other cells (30, 31, 39) . Recently, we identified Cas in platelets (33) and found that it undergoes changes upon platelet activation (34) . Therefore, we investigated tyrosine phosphorylation of Cas and FAK upon rhodocytin stimulation. FAK tyrosine phosphorylation occurred relatively late after stimulation and was dependent upon platelet aggregation (data not shown). On the other hand, Cas underwent tyrosine phosphorylation 15 s after stimulation, and the tyrosine-phosphorylated Cas was dephosphorylated after 1 min, as aggregation proceeded further (Fig.  6A) . Tyrosine-phosphorylated Cas may be dephosphorylated by the increased phosphatase activity mediated through GPIIb/ IIIa (34) . We also confirmed that Cas tyrosine phosphorylation is independent of platelet aggregation, which is distinct from FAK tyrosine phosphorylation (34) . The onset of Cas tyrosine phosphorylation was significantly earlier (15 s) than that of Syk or PLC␥2 (2 min after stimulation in both cases), which suggests that Cas tyrosine phosphorylation lies more proximal to GPIa/IIa than Syk or PLC␥2. Quantification of Cas tyrosine phosphorylation relative to Cas protein showed that PGE 1 pretreatment did not inhibit Cas tyrosine phosphorylation (Fig.  6B) . Under PGE 1 pretreatment, which inhibited platelet aggregation, the level of tyrosine phosphorylation was kept elevated 1 min after stimulation, whereas the tyrosine-phosphorylated Cas was dephosphorylated after 1 min without PGE 1 . This is in strong contrast to Syk and PLC␥2, the tyrosine phosphorylation of which was completely abrogated by PGE 1 . Since Cas is an adapter protein without kinase activity, a tyrosine kinase must be activated before tyrosine phosphorylation of these adapter proteins occurs.
Src Associates with Cas in a Manner Dependent upon Cas Tyrosine Phosphorylation-Several studies have suggested that Src, FAK, PYK2, or Fyn play an important role in Cas tyrosine phosphorylation in other cells (30, 32, 40 -43, 46, 48 -52) . Immunoprecipitation with an anti-Cas antibody, followed by Western blotting with an anti-Src mAb, revealed that Src associates with Cas upon GPIa/IIa stimulation (Fig. 6) . The association between Src and Cas appears to be related to the tyrosine-phosphorylated level of Cas. In contrast, we were unable to identify the co-presence of FAK, PYK2, Fyn, Lyn, or Syk in Cas immunoprecipitates (data not shown). These findings suggest that Src specifically associates with Cas and that Src but not FAK or PYK2 may phosphorylate Cas in platelets. We did not detect Cas in the immunoprecipitates of Src, probably because the total amount of Src in platelets far exceeds that of Cas in platelets (data not shown).
Src and Lyn Constitutively Associate with GPIa/IIa and the GPIa/IIa-associated Kinase Activity Rapidly Increases Upon
GPIa/IIa Stimulation-Immunoprecipitation of GPIa/IIa with an anti-GPIa antibody, followed by Western blotting with antibodies against FAK, Fyn, phosphatidylinositol 3-kinase, Lck, Jak1, Jak2, PTP1D/SHP2, Cas, Cbl, 14-3-3, and Fc receptor ␥-chain produced negative results, suggesting that these proteins do not associate with GPIa/IIa (data not shown). However, immunoprecipitates with anti-Src mAb or anti-Lyn pAb revealed that Src and Lyn constitutively associated with GPIa/ IIa and that Src but not Lyn dissociated from GPIa/IIa as platelets formed concrete aggregates (Fig. 7A ). Src and Lyn did not co-precipitate with control IgG (data not shown). In vitro kinase assays of GPIa/IIa immunoprecipitates revealed that the 60-kDa kinase activity increased 10 s after stimulation and completely disappeared 1 min after stimulation (Fig. 7B) . Lyn constantly associated with GPIa/IIa, even when the kinase activity was totally absent at 3 min. On the other hand, Src almost completely dissociated from GPIa/IIa 3 min after stimulation. Thus, the presence of Src correlates well with the GPIa/IIa-associated kinase activity. Since the Western-blotted membrane was incubated with KOH, to minimize serine/threonine phosphorylation, the kinase activity most probably belongs to a tyrosine kinase. The molecular mass of this autophosphorylated kinase, 60 kDa, is the same as that of Src but distinct from that of Lyn (56/53 kDa). None of other tyrosine kinases that exist in platelets were detected in GPIa/IIa immunoprecipitates. These findings strongly suggest that the GPIa/IIa-associated kinase activity belongs to that of Src. When platelets were pretreated with EGTA and GRGDS to inhibit platelet aggregation, the association between GPIa/IIa and Src/Lyn remained constant, regardless of GPIa/IIa stimulation (Fig. 8A, left panel) . Although the amount of GPIa/IIaassociated Src remained constant under GRGDS treatment, in vitro kinase assays of GPIa/IIa immunoprecipitates revealed that the 60-kDa kinase activity increased 10 -20 s after stimulation and decreased after 1 min (Fig. 8A) . We sometimes detected a yet unidentified 40-kDa phosphorylated protein. The pattern of the 60-kDa kinase activity was not greatly altered by PGE 1 ; it increased 10 -20 s after stimulation and decreased after 1 min (Fig. 8A, right panel, and Fig. 8B ). Taken together, we suggest that a change in the GPIa/IIa-associated Src activity is the most proximal step in the GPIa/IIa-mediated signal transduction.
PP1 Potently Inhibits Platelet Aggregation Induced by Rhodocytin-Since we found that GPIa/IIa-associated Src activity is the most proximal step in the GPIa/IIa stimulation, we next sought to investigate the effects of PP1, a specific inhibitor of Src kinase inhibitor, on platelet aggregation induced by rhodocytin. As shown in Fig. 9 , 5 M PP1 completely inhibited platelet aggregation induced by 10 nM rhodocytin, and this inhibitory effect was not overcome by the higher concentration of rhodocytin (100 nM). These findings suggest that Src is activated after rhodocytin stimulation and plays a functionally important role in rhodocytin-induced platelet aggregation.
Cytochalasin D Inhibits the Activation of GPIa/IIa-associated Kinase, Tyrosine Phosphorylation of Cas-Cytochalasin D, which disrupts actin filament organization, inhibits tyrosine kinase-mediated integrin signaling in several systems (44) . We have already shown that cytochalasin D inhibits platelet aggregation, intracellular calcium mobilization, and Syk or PLC␥2 tyrosine phosphorylation induced by rhodocytin (26) . In this study, we evaluated the effects of cytochalasin D on the signaling molecules more proximal to GPIa/IIa, which are the GPIa/IIa-associated kinase activity and Cas. As shown in 
DISCUSSION
Rhodocytin Induces Platelet Aggregation by Interacting with
GPIa/IIa-In the present study, we sought to identify the membrane molecule that rhodocytin binds and the mechanism by which it elicits platelet activation. Several membrane glycoproteins have been identified, which induce activation signals upon ligand binding. They include GPIb, Fc␥RII, GPIa/IIa, and GPVI. In a previous study, we found that echicetin, GPIbblocking snake venom, has no effect on rhodocytin-induced platelet aggregation (25) . We found in this study that IV.3, an anti-Fc␥RII antibody, did not inhibit platelet aggregation induced by rhodocytin. It is well known that FcR␥-chain physically associates with GPVI and plays a crucial role in the GPVI-mediated signaling pathway. It is reported that CRP, a GPVI agonist, fails to induce aggregation of Fc␥-deficient platelets (18) . In this study, aggregation of Fc␥-deficient platelets was induced by rhodocytin. These findings taken together suggest that rhodocytin induces platelet aggregation independently of GPIb, Fc␥RII, or GPVI. On the other hand, three anti-GPIa mAbs potently inhibited platelet aggregation induced by rhodocytin, suggesting that it interacts with GPIa/IIa, a collagen receptor on the platelet membrane. Furthermore, complete inhibition of platelet adhesion to rhodocytin by antiGPIa mAbs indicates that the major binding site of rhodocytin on the platelet membrane is GPIa/IIa.
Immunoprecipitation study using rhodocytin-coupled beads showed that rhodocytin indeed interacts with GPIa/IIa. We could not detect the association of GPIIa with rhodocytin-coupled beads, suggesting that rhodocytin binds to GPIa but not to GPIIa. Failure of anti-GPIIa antibody (100 g/ml of DE9) to inhibit rhodocytin (10 nM)-induced platelet aggregation also supports this hypothesis (data not shown). To determine whether rhodocytin directly binds to GPIa or indirectly via certain proteins on the platelet membrane, we performed binding studies of rGPIa/IIa liposomes to immobilized rhodocytin. We found that GPIa/IIa liposomes bound to immobilized rhodocytin in a dose-dependent manner and that this binding was totally inhibited by anti-GPIa mAbs. These findings clearly demonstrate that the rhodocytin binding to GPIa/IIa is direct and specific. Furthermore, the fact that the anti-GPIa antibodies inhibit rhodocytin-induced platelet aggregation suggests that the binding of rhodocytin to GPIa/IIa is functionally relevant.
To our surprise, EDTA did not inhibit the binding of rhodocytin to rGPIa/IIa liposomes at all. Most of the ligand-integrin interactions are dependent upon divalent ions and thus can be inhibited by EDTA (5) . To the best of our knowledge, echovirus 1 binding to integrin ␣ 2 ␤ 1 (GPIa/IIa) is the only case reported that is independent of divalent cations (45, 47) . The inhibitory effects of anti-␣ 2 (GPIa) or ␤ 1 (GPIIa) antibodies on echovirus binding to integrin ␣ 2 ␤ 1 also had a profile distinct from collagen fiber binding to integrin ␣ 2 ␤ 1 (47) . Later, they determined the binding site of echovirus 1 on the integrin ␣ 2 I domain, which is distinct from the metal ion-dependent adhesion site residues essential for the divalent cation-dependent interaction with collagen (53) . The binding site of rhodocytin on GPIa/IIa also appears to be different from that of collagen, and this may partly explain the several differences between rhodocytin-induced and collagen-induced signals. The binding site of rhodocytin on GPIa/IIa needs to be addressed in the future.
Relatively high concentrations of immobilized rhodocytin were required for rGPIa/IIa liposomes binding, compared with those required for eliciting platelet aggregation. This may be attributed to the possible reduction in the binding ability of rhodocytin to GPIa/IIa during the immobilization procedure. Alternatively, it is also possible that rhodocytin induces conformational changes of GPIa/IIa on the platelet membrane, as in the case of ligand binding to other integrins. Conformational changes of GPIa/IIa on the platelet membrane may result in the increased binding capacity of GPIa/IIa to rhodocytin, whereas this apparently cannot happen with rGPIa/IIa liposomes. Further experiments are needed to address this issue.
The Most Proximal
Step of the Rhodocytin-mediated Signal Transduction Pathway-We then investigated the activation signals most proximal to GPIa/IIa by the use of immunoprecipitation studies. Immunoprecipitation of GPIa/IIa, followed by Western blotting with anti-Src mAb or anti-Lyn pAb, revealed that Src and Lyn constitutively associated with GPIa/ IIa. GPIa/IIa-associated kinase activity increased upon rhodocytin stimulation, which was only slightly modified by PGE 1 treatment. We assume that this kinase activity belongs to that of Src, since its molecular mass, 60 kDa, is similar to that of Src, and no association was detected between GPIa/IIa and other major kinases present in platelets including FAK, Fyn, phosphatidylinositol 3-kinase, Lck, Jak1, and Jak2.
Furthermore, we found that PP1, an inhibitor of Src family kinases, completely inhibited rhodocytin-induced platelet aggregation at the concentration of 5 M. Higher concentrations of rhodocytin (up to 100 nM) could not overcome the inhibitory effect of PP1. We also examined effects of PP2, which is another inhibitor of Src family kinase, and we obtained results similar to that of PP1 (data not shown). Based on these findings, we assume that GPIa/IIa-associated Src is the most proximal step of the GPIa/IIa-mediated signal transduction pathway, although we cannot totally exclude the possibility that the Lyn kinase activity is also involved in rhodocytin-induced platelet activation via GPIa/IIa. Since Triton X-100 treatment does not completely disrupt the noncovalent bond between GPIa and GPIIa (data not shown), it is still premature to draw a conclusion as to whether Src associates with GPIa or GPIIa and which molecule plays a more important role in the GPIa/IIamediated signal transduction pathway.
From these findings described above, we suggest that rhodocytin mediates platelet activation signals through GPIa/IIa (integrin ␣ 2 ␤ 1 ). By analogy to integrin-mediated signaling pathways in other cells, in which FAK and Cas are involved, we evaluated the changes in FAK and Cas in rhodocytin-induce platelet activation. FAK tyrosine phosphorylation occurred relatively late and was dependent upon platelet aggregation. On the other hand we found that rhodocytin stimulation induced the level of Cas tyrosine phosphorylation 15 s after stimulation. Src but not FAK associated with Cas in a manner dependent upon the tyrosine phosphorylation of Cas. These findings suggest that, unlike other cells in which FAK phosphorylates Cas in an integrin-related activation, Src is responsible for Cas tyrosine phosphorylation in GPIa/IIa-related platelet activation. Since we previously found that ASA and PGE 1 potently inhibited platelet aggregation, intracellular calcium mobilization, and tyrosine phosphorylation of Syk and PLC␥2, we then examined the effects of these inhibitors on Cas tyrosine phosphorylation. Cas tyrosine phosphorylation was not inhibited by ASA (data not shown) or PGE 1 . The GPIa/IIa-associated Src activity enhanced upon rhodocytin stimulation was also resistant to ASA (data not shown) or PGE 1 treatment. This is in marked contrast to Syk and PLC␥2 tyrosine phosphorylation, Ca 2ϩ mobilization, and platelet aggregation, which are almost completely inhibited by these agents, suggesting that GPIa/IIaassociated Src activity and Cas tyrosine phosphorylation are located at the more proximal steps in the rhodocytin-mediated signaling pathway.
Based upon these findings, we propose the following steps for rhodocytin-induced platelet activation; the binding of rhodocytin to GPIa/IIa results in activation of Src, which constitutively binds to GPIa/IIa. Activated Src associated with GPIa/IIa then induces tyrosine phosphorylation of Cas. Several activation signals including Syk and PLC␥2 are also involved in rhodocytin-induced platelet activation.
The Similarities and Differences between Rhodocytin-induced and Collagen-induced Activation Signals-We suggest that rhodocytin induces platelet aggregation by interacting with GPIa/IIa, one of the most important collagen receptors. We found several similarities and differences between rhodocytin-induced and collagen-induced platelet activation, which may give insights into the platelet activation pathway related with collagen receptors.
1) Rhodocytin induces aggregation of Fc␥-deficient platelets, whereas collagen does not. The "two-site, two-step" theory has been proposed for collagen activation of platelets. Based on this notion, collagen first interacts with one type of collagen receptors, and then the second receptor is involved to induce full activation of platelets. The major role of GPIa/IIa for platelet adhesion and the lack of collagen-induced platelet aggregation in GPIa/IIa-deficient platelets have suggested that GPIa/IIa is the first receptor to react with collagen and plays the initial role in the collagen-platelet interaction. However, this notion was challenged by a recent report by Jung and Moroi (35) who suggest that GPVI activates GPIa/IIa through its inside-out activation pathway. Furthermore, CRP, which specifically interacts with GPVI, is a potent agonist of platelet activation in various aspects, whereas the peptides that specifically bind GPIa/IIa appear to induce no activation signal in platelets (64) . These findings have provided evidence for the major role of GPVI in collagen-induced platelet activation. In this aspect, it is of interest how rhodocytin elicits platelet aggregation by interacting with GPIa/IIa but not with GPVI. It is possible that the mode of binding between rhodocytin and GPIa/IIa, which is distinct from that between collagen fibers and GPIa/IIa, elicits intracellular activation signals that cannot be observed with the binding between GPIa/IIa and its specific peptides. Alternatively, it is possible that cross-linking of GPIa/IIa by rhodocytin may suffice to produce intracellular activation signals without the involvement of GPVI. Collagen fails to induce platelet aggregation in GPIa/IIa-deficient platelets, suggesting that the interaction between collagen fiber and GPVI does not lead to full activation of platelets. On the other hand, CRP, which binds only to GPVI potently, induces platelet aggregation. Thus extensive cross-linking of one type of collagen receptors may suffice to activate platelets, and the same mode of activation may be applied to that of rhodocytin.
It may be also argued that rhodocytin binds to yet unidentified molecules other than GPIa/IIa, although the interaction between rhodocytin and GPIa/IIa is essential. In this study, we showed by several lines of evidence that rhodocytin binds to GPIa/IIa but not to GPVI or GPIb. However, we cannot totally exclude the possibility that rhodocytin may have binding sites other than GPIa/IIa on the platelet membrane, and this may contribute to the initiation of activation signals. We need to address this issue in the near future.
2) It is reported that Fyn and Lyn but not Src are involved in the GPVI-mediated signal transduction pathway (15, 17) , whereas rhodocytin activates GPIa/IIa-associated Src. Ichinohe et al. (60) reported that collagen induces Src activation in GPVI-deficient platelets, and an anti-␣ 2 blocking antibody in-hibited this activation. The Src activation is most probably mediated through GPIa/IIa, although the involvement of other collagen receptors cannot be excluded. Our findings that rhodocytin induces the GPIa/IIa-associated Src kinase activity appear to be in good agreement with their study using GPVIdeficient platelets. Taken together, we suggest that Src activation is involved in the GPIa/IIa-mediated signal transduction pathway, whereas Fyn and Lyn are involved in the GPVI-mediated signal transduction pathway.
3) Cytochalasin D totally inhibited all the rhodocytin-elicited signals we evaluated in a previous study and this one. GPIa/ IIa-associated Src activation, Cas tyrosine phosphorylation, Syk and PLC␥2 activation, intracellular calcium mobilization, and platelet aggregation were completely blocked (26) . It is reported that several collagen-induced activation signals are also susceptible to cytochalasins (29, 62, 63) . On the other hand, cytochalasin D does not inhibit platelet aggregation, intracellular calcium mobilization, or tyrosine phosphorylation of Syk and PLC␥2 induced by CRP as we have previously reported (26) . Therefore, the susceptibility to cytochalasin D of collagen-induced platelet activation is most likely derived from the GPIa/IIa-mediated signaling pathway. There have been a number of reports (54, 56 -59) that suggest that integrin clustering, which is facilitated by cytoskeletal reorganization, activates tyrosine kinases associated with integrins. Since cytochalasin D interferes with cytoskeletal assembly, cell activation mediated by integrins is severely suppressed by cytochalasin D. Our findings that rhodocytin mediates tyrosine phosphorylation of several proteins via GPIa/IIa, which can be inhibited by cytochalasin D, fit well with this notion.
Susceptibility to cytochalasin D suggests that GPIa/IIa clustering is required to activate GPIa/IIa-associated Src. How does rhodocytin, which is a heterodimer of 18-and 15-kDa units (25) , induce GPIa/IIa clustering? In a preliminary experiment, we estimated the molecular mass of rhodocytin to be 61 kDa in water by gel filtrating chromatography. 2 Wang et al. (55) also isolated and partially characterized a protein whose structural and functional property is identical with rhodocytin, although the complete sequence awaits to be determined. This protein probably has a quaternary structure consisting of at least two disulfide-linked dimers since it has a native molecular mass of about 66 kDa as determined by gel filtration. Thus, rhodocytin appears to form a multimer in water. This multivalency in water may induce platelet activation by clustering GPIa/IIa. Cytochalasin D is likely to disturb GPIa/IIa clustering induced by rhodocytin stimulation, resulting in inhibition of the GPIa/ IIa-mediated signals from the most proximal step.
Alternatively, cytochalasin D may directly inhibit the signal transduction related to GPIa/IIa. It is known that GPIa/IIa is linked to the membrane cytoskeleton through association with actin-binding protein and short actin filaments. Therefore, disruption of actin polymerization may inhibit transducing GPIa/ IIa-mediated activation signals.
4) Although we found that rhodocytin-induced tyrosine phosphorylation of Syk and PLC␥2 was potently inhibited by ASA or PGE 1 , several reports (27) (28) (29) 61) suggest that tyrosine phosphorylation of several proteins induced by collagen is resistant to TXA 2 blocking or cAMP-elevating agents. These reports used high dose collagen (50 -150 g/ml) to prove the resistance of collagen-induced protein tyrosine phosphorylation to these inhibitors. It is well established that several parameters of platelet activation induced by low dose collagen are highly dependent on TXA 2 generation. In our work, 1 mM ASA or 1 M PGE 1 apparently inhibited Syk and PLC␥2 tyrosine phosphorylation induced by 10 g/ml collagen. The maximum level of PLC␥2 tyrosine phosphorylation induced by 10 g/ml collagen was decreased to 60% of the control by ASA treatment, and the peak time was delayed from 30 s to 5 min. 3 Thus, the inhibitory profile of these agents on low dose collagen stimulation is similar to that of rhodocytin, which seems to activate platelets by binding to GPIa/IIa. On the other hand, similar to high dose collagen, Syk and PLC␥2 tyrosine phosphorylation induced by GPVI agonists is not dependent on TXA 2 generation (26) or cAMP (27) . Taken together, we speculate that low concentrations of collagen mediate activation signals through GPIa/IIa and GPVI, whereas at high concentrations of collagen, signals from GPVI become predominant over those mediated by GPIa/IIa. 5) Rhodocytin, which binds to GPIa/IIa and not to GPVI, induces faint tyrosine phosphorylation of Syk, which typically peaks at 2 min after stimulation, whereas collagen induces marked phosphorylation of Syk in the early stage of activation. Others and we (26, 65) found that CRP that binds to GPVI also induces marked phosphorylation of Syk in the early stage of platelet activation, similar to collagen. Ichinohe et al. (60) reported that collagen-induced Syk tyrosine phosphorylation was severely compromised in platelets lacking GPVI. Our finding is in accordance with previous reports and confirms that GPVI is a main receptor that induces Syk tyrosine phosphorylation in collagen-induced platelet activation.
